Novartis Develops New Drug for Advanced Lung Cancer

by Julia Samuel on  February 28, 2015 at 3:40 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Swiss drug manufacturers Novartis have developed a drug for advanced lung cancer. European health regulators have recommended approval of the drug, which is intended to treat patients with a specific genetic mutation.
Novartis Develops New Drug for Advanced Lung Cancer
Novartis Develops New Drug for Advanced Lung Cancer

A new class medicines Zykadia, or ceritinib known as ALK (Anaplastic lymphoma kinase) inhibitors was approved last year in the United States.

It is designed for use in non-small cell lung cancer patients who have previously been treated with another ALK inhibitor, Pfizer's Xalkori.

The drug is targeted for a specific mutation of the ALK protein found mainly in 2 - 7 percent of non-small cell lung cancer patients.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Lung Biopsy Lung Cancer Malignant Mesothelioma Cancer and Homeopathy Clinical Trials - Different Phases of the trial Signature Drug Toxicity Cancer Facts Asbestosis Cancer 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive